The MHC class II deficiency syndrome: heterogeneity at the level of the response to 5-azadeoxycytidine.
The involvement of DNA methylation in aberrant MHC class II gene expression in EBV-transformed B-cell lines from 2 patients (THF and DGN) with the MHC class II deficiency syndrome (bare lymphocyte syndrome) was investigated. Incubation of the cells in the presence of various concentrations of 5-azadeoxycytidine resulted in the induction of expression of HLA DR genes in the DGN cell line, whereas, in the THF cell line, no effect of 5-azadeoxycytidine treatment on the expression of the HLA DR genes could be detected. Subsequent Southern blot analysis using methylation-sensitive restriction enzymes (ApyI, EcoRII and HhaI) and 5-azadeoxcycytidine-treated and untreated genomic DNA, indicated that the lack of HLA DR-A expression in the DGN cell line is not caused by hypermethylation of the 5' region of the HLA DR-A gene. These results indicate that 5-azadeoxycytidine treatment of the DGN cell line leads to activation of a methylation-sensitive factor that is involved in the regulation of transcription of the DR-A gene. In cell line THF, however, demethylation does not restore the activity of this factor. The lack of MHC class II expression in this cell line is caused by some other defect. The results of our analysis indicate that at least two different factors are involved in regulation of MHC class II gene expression.
Lambert
M
M
Department of Immunohaematology and Bloodbank, University Hospital, Leiden, The Netherlands.
van Eggermond
M C
MC
Kraakman
M E
ME
Schuurman
R K
RK
van den Elsen
P J
PJ
D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002461:Cell Line, Transformed; D004247:DNA / Q000032:analysis; D000077209:Decitabine; D005786:Gene Expression Regulation / Q000187:drug effects*; D005802:Genes, MHC Class II; D006681:HLA-D Antigens / Q000096:biosynthesis / Q000172:deficiency* / Q000235:genetics; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000235:genetics / Q000473:pathology*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D008745:Methylation; D011401:Promoter Regions, Genetic; D013577:Syndrome; D014158:Transcription, Genetic
D006681:HLA-D Antigens; D000077209:Decitabine; D004247:DNA; D001374:Azacitidine